LeMaitre Vascular, Inc. (NASDAQ:LMAT) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) have been given a consensus rating of “Moderate Buy” by the eight brokerages that are currently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year target price among brokers that have covered the stock in the last year is $105.80.

A number of research analysts recently commented on LMAT shares. Wall Street Zen upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Wells Fargo & Company raised their price objective on shares of LeMaitre Vascular from $87.00 to $94.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 26th. Citizens Jmp boosted their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Roth Mkm reaffirmed a “buy” rating and issued a $117.00 target price (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Finally, Weiss Ratings upgraded LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th.

LeMaitre Vascular Price Performance

LMAT opened at $108.49 on Friday. LeMaitre Vascular has a 1-year low of $71.42 and a 1-year high of $115.33. The stock’s fifty day simple moving average is $99.15 and its 200 day simple moving average is $90.66. The company has a current ratio of 12.89, a quick ratio of 10.95 and a debt-to-equity ratio of 0.43. The stock has a market cap of $2.47 billion, a PE ratio of 43.22, a price-to-earnings-growth ratio of 3.12 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 14.72%. The firm had revenue of $64.45 million during the quarter, compared to analysts’ expectations of $62.98 million. During the same period in the previous year, the business posted $0.49 earnings per share. The company’s revenue for the quarter was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, research analysts expect that LeMaitre Vascular will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 26th. Shareholders of record on Thursday, March 12th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.9%. The ex-dividend date was Thursday, March 12th. This is a positive change from LeMaitre Vascular’s previous quarterly dividend of $0.20. LeMaitre Vascular’s dividend payout ratio (DPR) is 39.84%.

Insider Transactions at LeMaitre Vascular

In related news, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $106.80, for a total transaction of $903,955.20. Following the transaction, the director directly owned 17,979 shares of the company’s stock, valued at approximately $1,920,157.20. This trade represents a 32.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 55,930 shares of LeMaitre Vascular stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $107.81, for a total transaction of $6,029,813.30. Following the completion of the sale, the chief executive officer owned 1,476,500 shares of the company’s stock, valued at $159,181,465. This trade represents a 3.65% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 215,438 shares of company stock valued at $23,062,911. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LMAT. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 1.4% during the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after purchasing an additional 21,946 shares during the period. First Trust Advisors LP grew its position in LeMaitre Vascular by 13.4% during the fourth quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock worth $76,245,000 after buying an additional 111,193 shares in the last quarter. State Street Corp grew its position in LeMaitre Vascular by 0.8% during the fourth quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock worth $65,447,000 after buying an additional 6,130 shares in the last quarter. Congress Asset Management Co. increased its stake in LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock worth $59,392,000 after acquiring an additional 40,065 shares during the period. Finally, Geode Capital Management LLC increased its stake in LeMaitre Vascular by 20.1% during the 4th quarter. Geode Capital Management LLC now owns 633,089 shares of the medical instruments supplier’s stock worth $51,351,000 after acquiring an additional 105,921 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.